Nature Reviews Clinical Oncology

Papers
(The TQCC of Nature Reviews Clinical Oncology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Clinical development and potential of photothermal and photodynamic therapies for cancer1510
Broadening horizons: the role of ferroptosis in cancer1095
Targeting apoptosis in cancer therapy1082
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood749
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors640
PD-L1 as a biomarker of response to immune-checkpoint inhibitors589
Immunotherapies for hepatocellular carcinoma578
Liquid biopsy enters the clinic — implementation issues and future challenges567
Exploring the NK cell platform for cancer immunotherapy547
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities540
Unlocking the potential of antibody–drug conjugates for cancer therapy466
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines446
TGFβ biology in cancer progression and immunotherapy381
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges374
Clinical and therapeutic relevance of cancer-associated fibroblasts369
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs369
Roles and mechanisms of alternative splicing in cancer — implications for care364
The emerging roles of circRNAs in cancer and oncology337
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways322
Immune-checkpoint inhibitors: long-term implications of toxicity313
Advancing therapy for osteosarcoma293
Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070288
Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic279
Harnessing cytokines and chemokines for cancer therapy277
T cell-engaging therapies — BiTEs and beyond274
The SWI/SNF complex in cancer — biology, biomarkers and therapy271
Current approaches to the management of brain metastases252
The adenosine pathway in immuno-oncology252
Rising incidence of early-onset colorectal cancer — a call to action250
Exploiting the folate receptor α in oncology246
Lineage plasticity in cancer: a shared pathway of therapeutic resistance241
Clinical relevance of tumour-associated macrophages224
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion222
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management213
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper203
Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives203
Predicting cancer outcomes with radiomics and artificial intelligence in radiology194
Understanding and overcoming resistance to PARP inhibitors in cancer therapy186
Nasopharyngeal carcinoma: an evolving paradigm186
Immunotherapeutic approaches for small-cell lung cancer186
Intratumoural administration and tumour tissue targeting of cancer immunotherapies181
Moving towards personalized treatments of immune-related adverse events177
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma167
Therapeutic targeting of the hypoxic tumour microenvironment167
Personalized early detection and prevention of breast cancer: ENVISION consensus statement159
Artificial intelligence in radiation oncology152
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?152
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome151
Clinical implications of T cell exhaustion for cancer immunotherapy151
Tumour budding in solid cancers150
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes147
The implications of IDH mutations for cancer development and therapy146
Targeting drugs to tumours using cell membrane-coated nanoparticles146
MET-dependent solid tumours — molecular diagnosis and targeted therapy146
CAR T cell therapies for patients with multiple myeloma144
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC138
Tissue-resident memory T cells in breast cancer control and immunotherapy responses137
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics137
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer132
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy126
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm126
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains125
Towards precision medicine for AML123
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management122
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety121
Immunogenicity of CAR T cells in cancer therapy121
ROS1-dependent cancers — biology, diagnostics and therapeutics118
Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire115
Senescence and cancer — role and therapeutic opportunities112
Fundamentals and developments in fluorescence-guided cancer surgery110
The current state of the art and future trends in RAS-targeted cancer therapies107
Precision oncology in metastatic colorectal cancer — from biology to medicine106
The nuclear export protein XPO1 — from biology to targeted therapy105
Integrating evolutionary dynamics into cancer therapy105
Is early-onset cancer an emerging global epidemic? Current evidence and future implications104
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion102
The emerging role of photoacoustic imaging in clinical oncology101
The blood–tumour barrier in cancer biology and therapy99
Tumour burden and efficacy of immune-checkpoint inhibitors98
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials94
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment91
Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice91
Circulating tumour DNA — looking beyond the blood87
Advancing therapy for neuroblastoma87
Long-term outcomes following CAR T cell therapy: what we know so far87
Radiotheranostics in oncology: current challenges and emerging opportunities84
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer84
Novel approaches to target the microenvironment of bone metastasis81
Protein degraders enter the clinic — a new approach to cancer therapy78
Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD75
Provision of cancer care during the COVID-19 pandemic72
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer69
COVID-19 and cancer: what we know so far67
Therapy with oncolytic viruses: progress and challenges66
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours65
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide64
Towards clinical translation of FLASH radiotherapy63
The emerging roles of γδ T cells in cancer immunotherapy60
Progress in refining the clinical management of cancer of unknown primary in the molecular era58
Beneficial autoimmunity improves cancer prognosis58
Consequences of COVID-19 for cancer care — a CRUK perspective57
Histology-agnostic drug development — considering issues beyond the tissue56
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention56
All change in the prostate cancer diagnostic pathway55
Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine55
Cancer and COVID-19 — potentially deleterious effects of delaying radiotherapy54
Harnessing cancer immunotherapy during the unexploited immediate perioperative period53
Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm53
Thermal immuno-nanomedicine in cancer51
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy50
Neoadjuvant therapy for pancreatic cancer49
Older adults with cancer and their caregivers — current landscape and future directions for clinical care47
The immune landscape of common CNS malignancies: implications for immunotherapy47
The multiple roles of LDH in cancer45
Humanized mouse models for immuno-oncology research45
Integrated MRI-guided radiotherapy — opportunities and challenges41
Harnessing big data to characterize immune-related adverse events38
Informative censoring — a neglected cause of bias in oncology trials38
The oligometastatic spectrum in the era of improved detection and modern systemic therapy37
Gut microbiota in colorectal cancer development and therapy36
New treatment strategies for advanced-stage gastrointestinal stromal tumours36
Criteria for the translation of radiomics into clinically useful tests35
Advances in the clinical management of uveal melanoma34
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells34
The global burden of lung cancer: current status and future trends33
Liquid biopsy for early stage lung cancer moves ever closer32
Treatment-free remission in patients with chronic myeloid leukaemia31
Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management30
Towards precision oncology with patient-derived xenografts29
COVID-19 and cancer: do we really know what we think we know?29
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer29
Predicting tumour radiosensitivity to deliver precision radiotherapy29
Systemic therapy for early-stage breast cancer: learning from the past to build the future29
0.024446964263916